FDA Warns Thrivelab Over Compounded Semaglutide Labeling and "Clinically Proven to Work" Claims
On June 8, 2026, FDA issued a warning letter to Thrivelab after a March 2026 review of thrivelab.com, which offers compounded semaglutide products. FDA says pictured compounded semaglutide products identify "thrivelab" on the label, "suggesting Thrivelab is the compounder of those drugs when in fact it is not," and cites claims including "Same active ingredient as Ozempic®" and "clinically proven to work," noting "Compounded drug products are not FDA-approved." FDA requested a written response within 15 business days.
What this means"Same active ingredient" marketing can blur the line between an FDA-approved drug and a compounded copy that has never been through FDA review — a distinction worth understanding before ordering through any telehealth platform.
Source: FDA original ↗